Connect with us

Health

EU Unveils Critical Medicines Act to Secure Drug Supply, But Key Questions Remain

Published

on

The European Commission has introduced the Critical Medicines Act, a major initiative aimed at strengthening the EU’s access to essential medicines. The proposal, unveiled this week, seeks to reduce dependency on non-EU suppliers, enhance joint procurement, and encourage European production. However, questions remain over its funding, stockpiling strategy, and potential trade risks.

‘Buy European’ Proposal Raises Trade Concerns

One of the Act’s most debated measures is the ‘Buy European’ rule, which would prioritize suppliers manufacturing a significant portion of critical medicines within the EU. The goal is to ensure a more reliable drug supply, but critics warn that this protectionist approach could trigger retaliation from global trade partners.

EU Health Commissioner Olivér Várhelyi defended the policy, calling it “a necessary step for public health security.” However, comparisons have been drawn to China’s ‘Buy China’ policy, which the EU itself has criticized for restricting foreign suppliers. If the EU moves forward with this approach, it could face trade tensions and reduced market access abroad.

Boosting European Production Without Full Relocation

The proposal also aims to reduce reliance on non-EU pharmaceutical production by promoting increased manufacturing within Europe. However, rather than requiring production to be strictly within EU borders, the plan emphasizes bilateral partnerships with neighboring countries such as the UK, Switzerland, and EU candidate nations.

“I rely on our closest neighbors to help bring production closer to the EU,” said Várhelyi, suggesting that strategic supply chain diversification is the Commission’s preferred approach over full relocation.

Funding Challenges Could Limit Impact

A key concern surrounding the Act is funding constraints. The Commission has allocated €83 million for 2026-2027, primarily from the EU4Health program. However, this budget is too small to support large-scale manufacturing shifts, raising doubts about the proposal’s effectiveness.

While additional funding could come from Horizon Europe and the Digital Europe Programme, 11 EU health ministers have called for defense funding to include medicine production, an idea that Várhelyi rejected. Instead, the Commission is loosening state aid restrictions, encouraging member states to fund production efforts themselves.

Strengthening Joint Drug Procurement

To improve purchasing efficiency, the Act enhances the EU’s joint procurement mechanism. Traditionally, the Commission and at least nine member states negotiate as a single bloc to secure better pricing and supply terms. The new proposal expands this approach, allowing the Commission to act as a central buyer upon request.

Additionally, a cross-border procurement model will be introduced, where the Commission provides logistical and administrative support to individual member states handling their own drug purchases.

Stockpiling Strategy Left Out

One of the biggest gaps in the proposal is the lack of a coordinated stockpiling framework. The Critical Medicine Alliance had recommended a harmonized EU-wide contingency stock, ensuring member states share supplies during shortages.

However, this was omitted from the final proposal, sparking concerns of fragmented and inequitable stockpiling across the bloc. Croatian MEP Tomislav Sokol warned that larger countries hoarding supplies at the expense of smaller nations must not happen again.

What’s Next?

As the Critical Medicines Act moves into the legislative process, MEPs are expected to push for amendments, particularly to address stockpiling coordination and funding gaps. While the proposal marks a major step toward securing Europe’s medicine supply, unresolved questions could shape its final impact in the coming months.

Health

Romania Faces Surging Measles Outbreak Amid Vaccine Hesitancy and Healthcare Challenges

Published

on

By

Romania is grappling with a severe measles outbreak, fueled by low vaccination rates, a struggling medical system, and widespread misinformation. While the country faces the largest measles crisis in Europe, experts warn that other nations may soon follow.

The outbreak, which has persisted for nearly three years, has intensified, with over 31,000 reported cases and 22 deaths in 2023 alone. Nearly half of the infections occurred in unvaccinated children under the age of five, highlighting the impact of Romania’s declining immunization rates. As of 2023, only 62% of the population was fully vaccinated against measles—well below the 95% threshold needed for herd immunity.

A Widening European Concern

While Romania remains the epicenter, measles is resurging across Europe. Countries such as Italy, Germany, Belgium, Austria, and France have each reported hundreds of cases in the past year, with numbers expected to rise.

“The challenge is all over the region,” said Dr. Dragan Jankovic, who oversees measles elimination at the World Health Organization (WHO) Europe office. “2024 was the worst possible year for measles in Europe since the 1990s. That’s why countries need to act now and start immunizing those who are unprotected.”

According to WHO data, only four EU countries—Hungary, Malta, Portugal, and Slovakia—currently meet the 95% vaccination target. The ongoing decline in routine childhood immunization since the COVID-19 pandemic has raised concerns that measles could become endemic in parts of Europe.

Why Vaccination Rates Are Declining

Romania’s vaccination rate was once on par with other EU countries, but the past decade has seen a sharp decline. A combination of factors—including vaccine hesitancy, supply shortages, healthcare system inefficiencies, and a mass exodus of medical professionals—has contributed to the crisis.

“It’s like the perfect storm ahead of an epidemic,” said Dr. Stefan Dascalu, an immunologist at Oxford University. “If you leave one of these problems untreated, it metastasizes.”

Public mistrust in vaccines deepened during the COVID-19 pandemic, when misinformation and conspiracy theories flourished. Anti-science rhetoric has also gained traction in Romania’s political landscape, with far-right parties leveraging vaccine skepticism to gain influence in parliament.

Romania’s healthcare system remains underfunded, with spending at just 5.8% of GDP—half the EU average. Many Romanians still perceive doctors as corrupt, making them more susceptible to vaccine misinformation. Additionally, while measles vaccines are free and recommended for children, they are not mandatory, and medical professionals are not always adequately trained to administer them or provide clear guidance.

Fighting Misinformation and Encouraging Immunization

Dr. Claudia Cojocaru, a neonatologist in Romania, has become an outspoken advocate for vaccinations after personally battling measles in 2019. She now works to counter vaccine misinformation among skeptical parents.

“I try not to push or mock them,” Cojocaru explained. “I tell them my messenger is always open. If they have concerns, they can ask me.”

Public health experts stress that reversing vaccine hesitancy and rebuilding trust in immunization programs will require long-term efforts, including stronger public health messaging, more investment in healthcare, and improved coordination across European nations.

“No single country is safe from the importation of the virus,” Jankovic warned. “If measles reaches unvaccinated populations, we will see more cases—and unfortunately, more outbreaks.”

Continue Reading

Health

Study Links Plant-Based Diet to Healthier Ageing

Published

on

By

A new large-scale study has found that following a predominantly plant-based diet while avoiding red meat and ultra-processed foods is associated with better physical and mental health in later life.

The study, published in Nature Medicine, tracked around 105,000 individuals in the United States over a span of 30 years. Researchers analyzed the impact of various dietary patterns, including the Mediterranean diet and the Dietary Approaches to Stop Hypertension (DASH) plan, on long-term health outcomes.

Findings indicated that those who aged healthily—reaching 70 without major chronic illnesses and maintaining good cognitive and physical function—followed diets rich in fruits, vegetables, whole grains, unsaturated fats, nuts, beans, and other legumes. They consumed moderate amounts of animal-based foods, such as low-fat dairy, while avoiding excessive sodium, sugary drinks, red and processed meats, and trans fats commonly found in fried foods.

According to Marta Guasch-Ferré, the study’s senior author and an associate professor at the University of Copenhagen, the research does not pinpoint a single optimal diet but rather emphasizes the benefits of multiple dietary approaches that support overall health. “Maybe there’s not a superfood or a diet that saves us all, but there are different diets that could improve our health,” she told Euronews Health.

Few Achieve Healthy Ageing

Despite the clear benefits of a nutritious diet, the study revealed that fewer than 10% of participants met the criteria for healthy ageing. Unlike previous research that focused mainly on lifespan, this analysis considered overall well-being, including mental health and physical independence.

“Do we really want to live longer, or do we want to live better?” Guasch-Ferré posed, highlighting the study’s emphasis on quality of life rather than longevity alone.

Though conducted in the U.S., researchers believe the findings are relevant to other regions, including Europe. However, they acknowledge certain limitations, such as potential influences from genetics, environment, and healthcare accessibility, despite efforts to account for socioeconomic factors.

Implications for Dietary Guidelines

The results suggest that dietary guidelines could be adjusted to promote healthier ageing, encouraging individuals to make more informed nutritional choices.

“Of course, healthy ageing is not just about diet,” Guasch-Ferré noted, but she emphasized that “any improvement in diet could help.”

The study adds to the growing body of evidence that lifestyle choices, particularly dietary habits, play a crucial role in maintaining health and well-being well into old age.

Continue Reading

Health

Europe Sees Surge in Stimulant Drug Use, Wastewater Analysis Reveals

Published

on

By

A comprehensive study of wastewater across Europe has revealed a significant rise in the consumption of stimulant drugs, particularly MDMA, cocaine, and amphetamines, across 128 cities in 26 countries.

The research, conducted by the European Union Drugs Agency (EUDA) and the SCORE group, examined the drug-taking habits of approximately 68.8 million people by analyzing wastewater samples. This method enables scientists to measure drug residues excreted in urine, providing an estimate of consumption levels within a given population.

According to the EU, 87 million adults in Europe have used illicit drugs at least once in their lifetime. While cannabis and cocaine remain the most widely used substances, the study noted an increasing trend in the use of MDMA, heroin, synthetic drugs, and psychedelics. The analysis focused on five key stimulants: amphetamine, cocaine, methamphetamine, MDMA, and ketamine, in addition to cannabis.

Cocaine Use on the Rise

The report highlighted that while cocaine use remained relatively stable between 2011 and 2015, consumption began rising significantly from 2016 onward. Western and southern European cities, particularly in Belgium, the Netherlands, and Spain, reported the highest levels of cocaine residues in wastewater.

The 2024 findings show further increases, with 39 of the 72 cities analyzed reporting higher levels compared to 2023. Belgium, in particular, recorded a sharp increase, with Brussels and Antwerp showing significant spikes in daily cocaine consumption. In Brussels, the daily intake per 1,000 inhabitants reached 1,186.34 milligrams in 2024, nearly double the 2023 figure of 598.22 mg. The study also found that cocaine use peaks on Saturdays, indicating its predominant recreational use.

MDMA and Ecstasy Consumption

Belgium, along with Czechia, the Netherlands, and Portugal, also recorded high levels of MDMA use. While ecstasy consumption has fluctuated since 2016, longer-term trends indicate overall growth. Similar to cocaine, MDMA usage is predominantly linked to recreational settings, with consumption surging over the weekends.

Decline in Cannabis Use

Despite the rise in stimulant drug use, cannabis, which remains the most commonly used illicit drug in Europe with an estimated 22.8 million users, saw a decline in consumption across most cities in 2024 compared to previous years.

Wastewater analysis indicates that cannabis use is more widespread in southern and central European countries, particularly Spain, the Netherlands, and Portugal. While cannabis remains illegal in most European nations, certain exceptions exist. Germany, Luxembourg, and Malta have legalized cannabis under specific conditions, while nine other countries allow limited consumption.

Shifting Drug Policies

The European Drug Agency’s 2024 report highlighted the ongoing debate surrounding cannabis regulation in the region. While discussions on policy changes continue, the agency stated that the future direction of European drug laws remains uncertain.

With stimulant use increasing across major cities and cannabis consumption showing a shift, the findings from this study provide valuable insights into the evolving drug landscape in Europe.

Continue Reading

Trending